The objectives of this thesis were to provide more insight into the risk and risk factors of adverse drug reactions associated with HIV-protease inhibitor treatment under non-experimental everyday circumstances. By recognition of risk factors, patients at risk can be identified beforehand and risk management can be targeted more efficiently, hence ultimately improving the safety of HIV-protease inhibitor treatment. In the studies presented in this thesis we applied multiple research strategies. tn which the nationwide ATHENA cohort played a central role.

, , , , , ,
The publication of this thesis was financially supported by Abbott BV, Boehringer Ingelheim BV, Bristol-Myers Squibb BV, Glaxo Smith Kline BV, Merck Sharp & Dohme BV and Roche Pharmaceuticals BV.
B.H.Ch. Stricker (Bruno)
Erasmus University Rotterdam
Erasmus MC: University Medical Center Rotterdam

Dieleman, J. (2002, June 12). Safety aspects of HIV-protease inhibitors. Retrieved from